



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



April 27, 2026

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Press Release for Audited Financial Results for quarter and year ended March 31, 2026

Dear Sir/ Madam,

In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of Press Release along with Investor's presentation for the Audited Financial results for the quarter and year ended March 31, 2026.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal

Company Secretary & Compliance officer



Jagsonpal Pharmaceuticals Ltd announces Q4 & FY26 Results

**Q4'FY26 Revenue up 10%; PAT up 31%; Cash position at ₹191 Cr
₹40 Cr Buyback Approved; 200% Dividend Proposed**

Gurugram, April 27, 2026: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the audited financial results for the quarter and year ended March 31, 2026.

₹ in Mn	Q4FY26	Q4FY25	YoY %	FY26	FY25	YoY%
Revenue	642	586	9.6%	2,872	2,687	6.9%
Operating EBITDA*	106	97	8.9%	609	579	5.2%
EBITDA Margin*	16.4%	16.6%	(20) bps	21.2%	21.5%	(30) bps
PAT **	88	67	31%	446	375	19%

**Operating EBITDA and EBITDA margins before ESOP | **Excluding exceptional items*

Q4 & FY26 Key Highlights:

Strategic Highlights

- **Proposed Buyback** – Up to 16 lakh equity shares (2.4% of total equity; 7.3% of non-promoter holding) at ₹250 per share with a total outlay of ₹40 Cr. Promoters shall not be participating in the same. This shall result in improvement of ROCE from 22.0% to 25.7% as well as ROE from 16.2% to 18.9%, reinforcing disciplined capital allocation and enhancing long-term shareholder value creation
- **Enhanced dividend** – Board has recommended higher dividend distribution at 200% (including 75% special dividend), resulting in a total cash outlay of ~₹262 Mn to shareholders

Financial Highlights

- **Topline trajectory driven by strong internal execution and demand momentum** - While Q4 revenue growth accelerated to ~10% on YoY basis, it grew by ~7% to ₹2,872 Mn.
- **Operational discipline sustains EBITDA Margins**- Op. EBITDA of ₹ 609 Mn for the full year with the margin of 21.2% while for Q4 EBITDA stood at ₹106 Mn, demonstrating efficient operating discipline.
- **Strong growth in net profits** – Operational PAT rose to ₹ 88 Mn in Q4 up 31%, while full year grew by 19% to ₹ 446 Mn on a YoY basis, with the margin of 15.5% underscoring sustained profitability momentum.
- **Robust cash flow generation** - Cash balance stood at ₹1,907 Mn as of Mar 31, 2026, an uptick of ₹ 451 Mn underscoring strong operational and financial discipline.

Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said,

“Our business regained traction in Q4 with growth of 10% on strength of sharper strategic execution. This is reflecting in our industry outpacing performance, with Pharmarack reflecting a 12.2% growth for Jagsonpal as compared to IPM growth of 8.6%. Our ‘Top 10’ brands which account for ~58% of revenues continue to drive performance.

Our yearly revenues grew 7% while our operating net profit grew 19% in the same period, with the year closing with a healthy cash position of ₹191 crores.

The Board has recommended a dividend of 200% (including a special dividend of 75%) for FY26. We will shortly be launching the proposed ₹40 crore buy-back at ₹250 per share as we received shareholder approval today. These shareholders-centric actions are reflective of our confidence in growth momentum of business in FY27 and beyond, with continued strong cash generation and improving ROCE/ROE.

We are confident of continued acceleration on all parameters given our focus on organic growth through improved MR productivity, strengthening key brands, and launching strategic new products, even as we look for value-accretive inorganic opportunities.”

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of ~1,000 professional sales representatives.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
Email: cs@jagsonpal.com , Tel: +91 124 4406710 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, Delhi, 110020 Corporate Office: Nimai Tower, 3 rd floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhaged Email- soumya@goindiaadvisors.com Mobile: +91-8619707750



Jagsonpal Pharmaceuticals Limited

Q4FY26 & FY26 Investor Presentation

27th April, 2026

Execution Speaks.

A year defined by delivery and built on disciplined execution



This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and several risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) change in the general market and macro-economic conditions, 2) governmental and regulatory trends, 3) successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 4) movements in currency exchange and interest rates, 5) increase in the competitive pressures and technological developments, 6) changes in the financial conditions of third parties dealing with us, 7) changes in laws and regulations that apply to our customers, suppliers and the pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Jagsonpal Pharmaceuticals Limited may vary materially from those described in the relevant forward-looking statements.

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation because of new information, future events or otherwise.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

Back On Growth. Ahead of the Market.



Jagsonpal grew 22.2% in Mar'26 vs. IPM's 10.1%, more than ***DOUBLE*** the market growth rate

Mar'26
Month

IPM (Market)

10.1%

Vs

Jagsonpal

22.2%

Outperformance: +1,210 bps

Jan–Mar'26
Quarter (Q4)

IPM (Market)

10.5%

Vs

Jagsonpal

14.2%

Outperformance: +370 bps

Mar'26
MAT (Annual)

IPM (Market)

8.6%

Vs

Jagsonpal

12.2%

Outperformance: +360 bps



Star Products: Niche Dominators Driving Growth

Top 10 brands constitutes ~ 58% of revenue, with 9 of them ranked in top #5

All values in ₹ Cr

Brand	Brand Rank	BRAND MAT			MOLECULE MAT		
		Mar'26	Mar'25	Gr%	Mar'26	Mar'25	Gr%
Indocap	1	39	37	5%	52	51	2%
Maintane IV	2	33	21	55%	156	132	18%
Metadec	2	25	23	9%	147	152	-4%
Lycored	1	20	18	10%	94	88	7%
Equirex	2	14	12	17%	116	111	5%
Divatrone	21	11	10	11%	1212	1151	5%
Maintane Tab	2	11	9	24%	27	22	22%
Endoreg	3	10	8	31%	93	98	-5%
Doxypal DR-L	4	8	8	-2%	241	242	-1%
PRU	4	7	5	27%	287	271	6%



Management Commentary



Manish Gupta
Managing Director

Our business regained traction in Q4 with growth of 10% on strength of sharper strategic execution. This is reflecting in our industry outpacing performance, with Pharmarack reflecting a 12.2% growth for Jagsonpal as compared to IPM growth of 8.6%. Our 'Top 10' brands which account for ~58% of revenues continue to drive performance.

Our yearly revenues grew 7% while our operating net profit grew 19% in the same period, with the year closing with a healthy cash position of ₹191 crores.

The Board has recommended a dividend of 200% (including a special dividend of 75%) for FY26. We will shortly be launching the proposed ₹40 crore buy-back at ₹250 per share as we received shareholder approval today. These shareholders-centric actions are reflective of our confidence in growth momentum of business in FY27 and beyond, with continued strong cash generation and improving ROCE/ROE.

We are confident of continued acceleration on all parameters given our focus on organic growth through improved MR productivity, strengthening key brands, and launching strategic new products, even as we look for value-accretive inorganic opportunities.

**High
Governance
Standards**

**Innovation
Backed Portfolio
Expansion**


**Financial
Strength fuels
Strategic Agility**

Growth levers – Built Internally, Visible Externally




Strong Financial Discipline



■ Revenue from Operations (₹ Mn)



■ PAT (₹ Mn)*



Strengthened Internal Execution



- Enhanced MR productivity through focused training
- Building high effort Sustainable growth with Rx brands, both Existing & New Brand launches
- Cost optimization supporting margin improvement
- Tight working capital and financial discipline with NWCC of 11 days constituting 4% of sales
- Efficient capital allocation balancing growth and returns


* Represents PAT before exceptional items

Disciplined Capital Allocation: Enhanced Dividends + Buyback



Strong FCF -> Delivering shareholder returns through multiple levers

■ FCF (₹ Mn)



Dividend : 100%
ROE: 12%
ROCE: 16%

Dividend : 125%
ROE: 16%
ROCE: 21%

Dividend : 200%
(includes Special Dividend of 75%)
ROE: 19%
ROCE: 26%

“Debt-free balance sheet and strong cash flows support disciplined capital allocation – returning capital to shareholders while remaining focused on selective, value-accretive acquisitions.”



Proposed Buyback : No promoter participation, Pure shareholder value

DETAILS OF THE BUYBACK

Up to 16 lakh equity shares (2.4% of total equity shares; 7.3% of non promoter shareholding of the company)
 Value: ~ ₹ 40 Cr (~18.4% of the total paid-up equity share capital and free reserves)
 Price: ₹250, a premium of ~ 40% to market price as on March 12, 2026 (Buyback Announcement Date)

RATIONALE

Asset Light Business Model

Requiring insignificant capital to scale-up, other than for inorganic initiatives


High Cash Generating Operations

Added over ~ ₹ 197 Cr of free cash between FY23-25, with current free cash of ~ ₹ 191 Cr.

Significant Shareholder value

Improvement of ~ 370 bps in ROCE, ~270 bps in ROE

UPDATES – PRE AND POST BUYBACK*



*Assumes 100% participation in Buyback | EPS : calculated basis the number of outstanding shares as on 31st March 2026



Giving Back – 200% Dividend for the Investors



Dividend Metrics






Balance Sheet Strength as of March 31st, 2026

Current Cash Position: ₹ 190.7 crores | Free Cash Flow: ₹ 61.4 crores

* Considered as per current shareholding

Growing track record of dividend payout



Topline grows. Bottomline accelerates.



Q4FY26 : Revenue up 10%, PAT up 31%, cash position of ₹191 Cr




Topline trajectory driven by strong internal execution and demand momentum

FY26 revenue grew ~7% YoY to ₹2,872 Mn, supported by portfolio strength and focused execution, while Q4 accelerated to ~10% growth on a YoY basis.



Operational discipline sustains EBITDA Margins

Op. EBITDA of ₹ 609 Mn for the full year with the margin of 21.2% while for Q4 EBITDA stood at ₹106 Mn, demonstrating efficient cost management and operating resilience.



Profitability surge led by operating leverage with ESOP cost materiality normalizing.

Profit rose to ₹ 88 Mn in Q4 up 31%, while full year Operational PAT grew 19% YoY to ₹ 446 Mn with the margin of 15.5% underscoring sustained profitability momentum.




Robust cash flow generation


Cash balance surged to ₹ 1,907 Mn as of Mar 31, 2026, an uptick of ₹ 451 Mn underscoring continued cash generating capability.

Financial Highlights: Q4FY26


Revenue from Operations




Gross Profit & Margin (%)



EBITDA & Margin (%) *



PAT & Margin (%) *



(All values in ₹ Mn)




* EBITDA and EBITDA margin is calculated Pre-ESOP, PAT & PAT Margin is calculated before exceptional items

Financial Highlights: FY26




(All values in ₹ Mn)


Revenue from Operations




Gross Profit & Margin (%)



EBITDA & Margin (%) *



PAT & Margin (%) *



■ FY25 ■ FY26

Income Statement



(All values in ₹ Mn)

Particulars	FY26	FY25	Y-o-Y	Q4FY26	Q4FY25	Y-o-Y
Revenue from Operations	2,872	2,687	6.9%	642	586	9.6%
Total Expenses	(2,263)	(2,108)	7.4%	(537)	(489)	9.8%
EBITDA*	609	579	5.2%	106	97	8.9%
EBITDA Margin*	21.2%	21.5%	-1.6%	16.4%	16.6%	-0.8%
Other Income	120	82	46.5%	32	28	14.4%
ESOP Cost	(28)	(68)	-	6	(10)	-
Depreciation	(94)	(81)	16.1%	(23)	(23)	0.6%
EBIT	606	511	18.6%	120	92	30.8%
EBIT Margin	21.1%	19.0%	10.9%	18.7%	15.7%	19.3%
Finance Cost	(10)	(10)	7.3%	(3)	(3)	-2.7%
PBT	596	502	18.8%	118	89	31.8%
PBT Margin	20.7%	18.7%	11.1%	18.3%	15.2%	20.2%
Exceptional Items (net of taxes)	(16)	179	-	0	(2)	-
Tax (Business profits)	(150)	(127)	18.1%	(30)	(22)	36.4%
PAT	431	554	-22.2%	88	66	33.0%
PAT Margin	15.0%	20.6%	-27.2%	13.6%	11.2%	21.3%

Key Balance Sheet Items



(All values in ₹ Mn)

Particulars	31-Mar-26	31-Dec-25	31-Mar-25
Shareholders Funds	2,762	2,657	2,399
Tangible Assets	6	6	6
Intangibles	780	798	856
Right of Use Assets	68	72	82
Cash & Equivalents	1,907	1,757	1,456
Other Non-Current Assets (Net)	26	32	47
Lease liabilities	82	85	92
Net Working Capital	110	126	93

The Growth Strategy

Strategic New Product Launches

- Flagship brands launches aligned with long-term growth vision
- Entry into growth segments of our core therapies

Rx lead Volume Growth


- Patient centric approach
- Overweight Incentives towards Rx Brands

Margin-Accretive Growth

- Focus on Non-NLEM Portfolio
- Competitive Pricing with Quality

Specialist-Led Market Penetration

- Speciality building for capital efficiency
- Engaging prescribers with Digital engagement





MySakhi Initiative

Where Business Meets Social Impact



Shaping the Future

Expanding outreach with self-testing kits, discounted lab tests, and an online forum to support women's holistic well-being.

Driving Menopause Awareness

Deliver impactful virtual sessions on menopause, supported by social media campaigns and community engagement.

Empowering Women Through MySakhi.in

A dedicated website offering educational resources, health tools, and community support focused on women's health

Transforming Hygiene Access

Built modern sanitation complexes across Punjab, Haryana, and Uttarakhand, fostering health and dignity for schoolgirls



18 pink toilets built in Haryana, Punjab, Uttarakhand & Delhi NCR Regions


Ongoing webinars, spearheaded by specialist doctors focused on Menopause awareness

Collaborating with NGOs for hygiene awareness and infrastructure development

Key CSR Highlights - FY26



Sanitation



Empowering education with dignity and hygiene

- 9 toilet blocks constructed during FY 25-26 across Gurugram, Punjab & Maharashtra, taking the total to 18 toilet blocks
- Installation of Sanitary Pad Vending Machines and Incinerators to promote menstrual hygiene management
- **9,576** girl students benefited through improved sanitation facilities

Awareness



Creating safe spaces and healthier lives

- **My Sakhi Initiative:** Collaborating with doctors to promote awareness on women's health and wellness
- Conducted 24 Webinars, engaging 1,309 participants
- Topics covered menopause, nutrition, bone health, mental wellness, and more

Relief



Standing with communities in times of crisis

- Provided financial aid to flood-affected communities in Punjab
- Provided medicines to affected public
- Timely access to essential healthcare support during emergency conditions
- Supporting communities beyond ongoing CSR initiatives

About the Company



Jagsonpal - Legacy of 'Quality and Trust' since 1964



100% India Centric Business
PAN India Presence;
Sub-chronic Presence

Deep Market Penetration
Presence across 4,000+ towns and cities through 1,200+ distributors, enabling wide accessibility and consistent brand recall.

Quality culture imbibed across Operations
CMOs fully compliant with WHO-GMP and ISO 9001:2015 standards with over 300+ quality checks

Enduring Doctor Confidence
Trusted by >50,000 doctors nationwide – a legacy of prescription confidence built over decades

Therapy powerhouse with deep domain expertise
Spanning branded generics, trade generics & OTC; Ranked #8 in CVM

Power Brand portfolio boosting market share
Top 10 contributing 58% of sales; includes 9 brands in 'Top 5'

Inorganic growth capabilities, supported by strong balance sheet
Demonstrated strategic acquisition with disciplined integration, driving profitability and margins

Lean Operations: Asset Light Model
Outsourced R&D and Manufacturing; built for growth without capital strain

Backed by promoter conviction, long term vision
Strategic alignment towards long term value creation

Strong Presence in Key Therapies



Gynecology

- 7th as per CMARC RPM in CVM
- Reaching ~90% of the Gynecologists nationwide, engagement with 35,000 out of 39,000 gynes
- Leaders in Progesterone therapeutic segment

Orthopedics

- 2nd as per CMARC RPM in CVM
- Reaching ~80% of the Orthopedists through consistent engagement with 10,000 out of 13,000
- Strong presence in Osteoporosis and Osteoarthritis segment

Ranked 8th in Corporate CVM (as per CMARC RPM)

Pediatrics

- 17th as per CMARC RPM in CVM
- Maintaining regular connect with 9,700 out of 35,650 Pediatricians, ensuring ~27% coverage
- Key segments include Gut Health (Probiotic), Cough, Cold & Fever, Anti-itch, Diarrhea and Dysentery

Dermatology


- 30th as per CMARC RPM in CVM
- Operates in Demelanizing, Antifungals and Anti-histamines segments
- Regular connect with ~4,500 out of 11,500 Dermatologists in India, ensuring ~40% coverage

Building A High-impact Asset Light Model





Strategic Pillars





Diverse Board; Strong Independent Directors



Debasis B Nandy
Independent Director
(CFO of Thomas Cook)

More than 30 years of experience across the financial domain including Accounts & MIS, Tax, Treasury, Budgeting and Planning, Business Finance, Mergers & Acquisitions and Investor Relations



Radhika M Dudhat
Independent Director
(Partner, Shardul Amarchand Mangaldas & Co.)

Chairperson of Corporate Law and Governance Sub-Committee of IMC Chamber of Commerce & Industry.



Pallavi D Gupta
Independent Director
(Partner, S.R. Dinodia & Co. LLP)

Serves as a member of global governing council for MGI Worldwide – one of the largest global networks of accounting, audit and taxation firms

Governance Framework





Statutory Auditors:
Walker ChandioK

Internal Auditors:
S S Kothari & Mehta

Cost Auditors:
Kirit Mehta & Co.

5-Year journey in a nutshell

(All values in ₹ Mn)





Thank You

Feel free to reach out to us if you have any questions

JAGSONPAL PHARMACEUTICALS LTD.

Corporate Office: Nimai Tower, 3rd Floor,
Plot No. 412-415, Phase-IV, Udyog Vihar,
Gurugram -122015, Haryana (India)



cs@jagsonpal.com



www.jagsonpal.com



+91 124 4406710

INVESTOR RELATIONS

Soumya Chhajed

Email: soumya@goindiaadvisors.com

Ph: +91 8619707750

